Camurus expands Eli Lilly collaboration to include amylin receptor agonists

Key facts

• Camurus announced Eli Lilly and Company exercised an option to include amylin receptor agonists in their collaboration.
• The decision extends Lilly's development rights for novel therapeutics.
• The original collaboration and license agreement was entered into in June 2025.

This expansion of the existing collaboration between Camurus and Eli Lilly signifies Lilly's interest in advancing the development of amylin receptor agonists. For Camurus, it represents a validation of their research and a potential for further revenue generation through the expanded agreement.